Tarik Möröy is the 5th President and Scientific Director of the Institut de recherches cliniques de Montréal (IRCM) – a position that he holds since 2006. He is also the Director of the Hematopoiesis and Cancer research unit and Full IRCM Research Professor. He also holds the Canada Research Chair (Tier 1) in Hematopoiesis and Immune Cell Differentiation since 2007 (renewed in 2014). He is also Full Research Professor in the Department of microbiology, infectiology and Immunology at the Université de Montréal. Moreover, he is adjunct professor in the Division of Experimental Medicine at McGill University. He has trained over 60 postdoctoral fellows and graduate students.
As the IRCM’s President and Scientific Director, he provides leadership for 35 principal investigators with research and/or clinical expertise in the fields of cancer, cardiovascular and respiratory disease, neurobiology, immunology, medicinal chemistry and ethics. He is responsible for strategic planning; researcher recruitment (14 new researchers were recruited since 2007); the institute’s funding; university, hospital and government relations; Master’s, doctorate and post-doctorate training; public communications and education; operations of the IRCM clinic; and overseeing the budget of one of Canada’s leading biomedical research institutions. Under his management, the IRCM vastly expanded its technical core facilities services (genomics, proteomics, and bioinformatics) and created a graduate program focused on translational research in order to bridge the gap between basic laboratory research and the needs of the clinical practice, thus accelerating the shift towards personalized medicine. These initiatives centered around the desire to “provide passionate researchers with the ideal conditions to experiment with their boldest ideas, test their theories and pave their own way for the benefit of us all.”
Dr. Möröy has authored more than 280 publications, including 152 original articles in specialized journals (many in highly-renowned peer-reviewed journals) in addition to numerous book chapters and scientific meetings. He is an editor for important journals such as The International Journal of Biochemistry and Cell Biology, American Journal of Blood Research and Scientific Reports. Dr. Möröy regularly reviews grants for funding agencies such as Germany’s Deutsche Forschungsgemeinschaft and the Leukemia & Lymphoma Research in the United Kingdom. In 2012, he was appointed as a scientific reviewer for the “Excellence Initiative” by the German Council of Science and Humanities. In 2014, he received a recognition award from the Leukemia and Lymphoma Society. In 2015, he was elected to the Board of Directors of the Canadian Society for Molecular Biosciences and appointed “Honorary Guest Professor” by the Capital University in Beijing for outstanding achievements in immunology.
Tarik Möröy obtained his PhD in biochemistry in 1987 from the Ludwig-Maximilians University in Munich (Germany), after conducting his doctoral experimental research at the Institut Pasteur in Paris from 1984 to 1987. From 1988 to 1991, he was a postdoctoral fellow at Columbia University in New York. Upon his return in Germany, he became an assistant professor at the Institut für Molekularbiologie und Tumorforschung of Philipps University in Marburg, where he also obtained his accreditation to supervise academic teaching and research. In 1995, he was promoted to associate professor and, one year later, to full professor in molecular cell biology in the Faculty of Medicine at Duisburg-Essen University. In addition to being a researcher and a professor at the university’s Cellular Biology Institute (Institut für Zellbiologie, IFZ), he also held important administrative duties including that of Executive Director of the IFZ from 1996 to 1999 and again from 2002 to 2005, and Chairman of the Board of the Center for Medical Biotechnology from 2003 to 2005. During this period, he led numerous federally- and European Union-funded research consortia in Germany. He also acted as an evaluator for the Marie Curie training programs, as well as an advisor for the Institut national de la santé et de la recherche médicale (INSERM) and other scientific advisory boards